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Neutralization or deletion of tumor necrosis factor
(TNF) causes loss of control of intracellular patho-
gens in mice and humans, but the underlying mech-
anisms are incompletely understood. Here, we
found that TNF antagonized alternative activation
of macrophages and dendritic cells by IL-4. TNF
inhibited IL-4-induced arginase 1 (Arg1) expression
by decreasing histone acetylation, without affecting
STAT6 phosphorylation and nuclear translocation.
In Leishmania major-infected C57BL/6 wild-type
mice, type 2 nitric oxide (NO) synthase (NOS2)
was detected in inflammatory dendritic cells or
macrophages, some of which co-expressed Arg1.
In TNF-deficient mice, Arg1 was hyperexpressed,
causing an impaired production of NO in situ. A
similar phenotype was seen in L. major-infected
BALB/c mice. Arg1 deletion in hematopoietic cells
protected these mice from an otherwise lethal
disease, although their disease-mediating T cell
response (Th2, Treg) was maintained. Thus, dele-
tion or TNF-mediated restriction of Arg1 unleashes1062 Cell Reports 15, 1062–1075, May 3, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://the production of NO by NOS2, which is critical for
pathogen control.INTRODUCTION
Myeloid cells such as macrophages play pivotal roles in the
immune system. They are essential for the uptake, killing, and
degradation of pathogens, the processing and presentation of
antigens, and the activation of effector T cell populations but
also for the termination of T cell responses, the resolution of
inflammatory processes, and for tissue homeostasis. The func-
tional diversity of macrophages largely results from exposure
to different microenvironmental cues, including cytokines and
tissue-specific signals (Ginhoux et al., 2015; Lavin et al., 2014).
Whereas interferon (IFN)-g and tumor necrosis factor (TNF) are
associated with the induction of classically activated or M1-like
macrophages expressing anti-microbial effector functions, cyto-
kines such as interleukin (IL)-4, IL-10, IL-13, or transforming
growth factor (TGF)-b limit the release of proinflammatory factors
by macrophages and promote macrophage phenotypes that
suppress T cell responses and/or support tissue repair (Gin-
houx et al., 2015). Thesemacrophages, whichwere operationally
dubbed suppressor (Kirchner et al., 1975), deactivated (Tsuna-
waki and Nathan, 1986), alternatively activated (Stein et al.,creativecommons.org/licenses/by-nc-nd/4.0/).
1992), or M2 (Mills et al., 2000), depending on their exact secre-
tory and immunomodulatory function and surface phenotype,
are characterized by distinct transcriptional and proteomic pro-
files (Murray et al., 2014). IL-4, for example, causes upregulation
of the mannose receptor 1 (Mrc1; CD206), the chitinase-3-like-
protein 3 (Ym1, Chi3l3), the resistin-like molecule alpha (Relma,
Retnla; also termed ‘‘found in inflammatory zone-1’’ [Fizz1]),
macrophage galactose-type C-type lectin 2 (Mgl2; CD301b),
programmed death ligand 2 (Pdl2; CD273), or arginase 1 (Arg1).
Arg1 is a cytosolic enzyme that hydrolyzes L-arginine into urea
and ornithine. It is a constitutive and essential component of the
hepatic urea cycle, which explains the postnatal lethality of
Arg1/ mice (Iyer et al., 2002), but it is inducible in many other
cell types, including macrophages and endothelial and epithelial
cells (Morris, 2009). In the immune system, arginine metabolism
by Arg1 has been conceptually linked to three major processes.
First, because ornithine is a precursor of the polyamines or
proline required for cell proliferation or collagen synthesis,
respectively, Arg1 expression is characteristic for wound healing
and tissue regeneration, whereas excessive Arg1 activity can
cause organ fibrosis (Wynn et al., 2013). Second, Arg1 expres-
sion by suppressor myeloid cells might deprive T cells of arginine
and thereby impair their activation and proliferation during anti-
infectious or anti-tumor immune responses (Bogdan, 2015;
Pesce et al., 2009). Third, Arg1 competes with inducible nitric
oxide (NO) synthase (iNOS) or type 2 NO synthase (NOS2), a
key anti-microbial and immunoregulatory pathway, for the com-
mon substrate L-arginine (Bogdan, 2015; El-Gayar et al., 2003;
Rutschman et al., 2001). Accordingly, Arg1 activity is correlated
with increased pathogen loads in infectious diseases (De
Muylder et al., 2013; Iniesta et al., 2005; Kropf et al., 2005). How-
ever, Arg1 was also observed to limit immunopathology and
fibrosis (Pesce et al., 2009) and to prevent microbial growth,
notably in the absence of NOS2 activity (Duque-Correa et al.,
2014).
Due to the diverse and possibly pathological effects of
Arg1, its expression requires tight control. In the past, research
focused on defining factors that upregulate Arg1. Several studies
revealed that not only cytokines but also microbes or microbial
products (DeMuylder et al., 2013; El Kasmi et al., 2008), hypoxia,
or lactic acid (Colegio et al., 2014; Louis et al., 1998) induced
Arg1. In contrast, the negative regulation of Arg1 in situ during
infections has not yet been addressed.
TNF is essential for the defense against intracellular microor-
ganisms and for maintaining lifelong control of latent pathogens.
Experiments with anti-TNF antibodies, tumor necrosis factor re-
ceptor (TNFR)/, or Tnf/ mouse strains, as well as treatment
of humans suffering from autoimmune diseases with TNF antag-
onists, have demonstrated the protective role of TNF (Allenbach
et al., 2008; Flynn et al., 1995; Grivennikov et al., 2005; Marino
et al., 1997; Novosad and Winthrop, 2014; Pfeffer et al., 1993;
Vassalli, 1992). However, the TNF-mediated molecular mecha-
nisms of pathogen control in vivo are still poorly defined. Tnf/
C57BL/6 mice locally infected with the protozoan parasite
Leishmania major (FEBNI strain) succumbed to progressive
cutaneous and visceral disease (Wilhelm et al., 2001). Unexpect-
edly, the development of type 1 T helper (Th1) cells and the
expression of NOS2, which are strictly required for the resolutionof Leishmania infections (Diefenbach et al., 1998; Liew et al.,
1990), were preserved in Tnf/mice (Wilhelm et al., 2001), lead-
ing to interest in identifying the mechanism that underlies the
exquisite susceptibility of this mouse strain.
Here, we tested the hypothesis that TNF causes protection by
inhibiting the expression of Arg1 and the development of alterna-
tively activated macrophages. We observed a strong negative
regulatory effect of TNF on Arg1 expression in macrophages
and dendritic cells. In L. major-infected wild-type (WT) mice,
Arg1 was weakly expressed. In Tnf/ mice, Arg1 was strongly
upregulated, leading to a frequent co-expression of Arg1 and
NOS2 in monocyte-derived dendritic cells or macrophages.
This impeded the production of NO in situ, a phenotype that
was shared by highly susceptible BALB/c mice. Cell-type-spe-
cific deletion of Arg1 prevented an otherwise lethal course of
infection.
RESULTS
TNF Inhibits the IL-4-Induced Expression of Arg1 and
Other M2 Markers
Wefirst tested the effect of TNFon the IL-4-inducedArg1 expres-
sion in bone marrow-derived macrophages (BMMs) and bone
marrow-derived dendritic cells (BMDCs). Simultaneous addition
of TNF caused downregulation of Arg1 mRNA and protein in
BMMs (Figures 1A–1C). The suppression of Arg1 protein was
more prominent at higher TNF/IL-4 ratios (Figure S1A), except
for IL-4 concentrations (%1 ng/ml) that were too low to induce
Arg1 protein above control levels (Figures S1B and S1C). In
time course experiments, the inhibitory effect of TNFwas notice-
able once Arg1 mRNA or protein was induced by IL-4 above the
level of unstimulated cells (Figures 1D and 1E). TNF alone
induced NOS2 mRNA in BMMs and, at high concentrations,
NOS2 protein and activity (Figures 1A, 1B, 1E, and 1F).
The suppressive activity of TNF on IL-4-triggered Arg1 expres-
sion was largely independent of NOS2-derived NO (Figure S1D),
maintained in macrophages that were infected with L. major
(Figure S1E), and observed with BMDCs (Figures 1F and S1C)
and resident peritoneal macrophages (data not shown). In both
BMMs and BMDCs, the effect was somewhat more pronounced
when the cells were derived from Tnf/ mice (Figures 1F and
S1C); cultures from Tnf/ BMDCs, however, did not differ
from WT BMDCs in the total yield of cells, the dendritic cell
maturation state (expression of CD40, CD80, CD86, and major
histocompatibility complex [MHC] class II) or the expression of
TNFR1 (CD120a) and TNFR2 (CD120b) (data not shown).
In addition to Arg1, TNF antagonized the IL-4-mediatedmRNA
upregulation of the M2markers Retnla and Ym1, whereas others
(Mgl2,Mrc1) were not affected (Figure S1F). To further corrobo-
rate that TNF counteracts the development of M2macrophages,
we analyzed the metabolism of BMMs. As expected (Huang
et al., 2014; Vats et al., 2006), IL-4 caused a shift toward mito-
chondrial oxidative phosphorylation via upregulation of the tran-
scriptional PPARg-coactivator-1b (PGC-1b), leading to amarked
rise of the maximal oxygen consumption rate (OCR). TNF-stimu-
lated BMMs, in contrast, showed an increased extracellular
acidification rate (ECAR), indicating that they rely on aerobic
glycolysis. Simultaneous addition of IL-4 and TNF to unbiasedCell Reports 15, 1062–1075, May 3, 2016 1063
Figure 1. TNF Inhibits the Expression of Arg1 in BMMs and BMDCs
(A–F) BMMs (A–F) or BMDCs (F) of C57BL/6 WT (A–E) or Tnf/ mice (F) were cultured with or without IL-4 (0.5–10 ng/ml) or TNF (10 or 50 ng/ml) for 1–24 hr,
followed by the determination of NO2
 in the supernatants (B and E). (A and D) A qRT-PCR analysis of BMMs. Results were calibrated to the medium value and
represent means ±SEM of six to eight (A) or two to four (D) experiments. *p < 0.05; **p < 0.01; ***p < 0.005, two-tailedMann-Whitney U test comparing IL-4 ± TNF.
(B, E, and F) Western blot analysis of BMMs or BMDCs. One of three (B), two (E), or four (F) experiments. (C) CLSFM of BMMs. One of three experiments.
See also Figures S1A–S1F.BMMs prevented the induction of Pgc-1bmRNA by IL-4 and the
subsequent metabolic changes (Figures 2A and 2B).
Because the IL-4-induced expression of Arg1 and Pgc-1b
strictly depends on Stat6 (Rutschman et al., 2001; Vats et al.,
2006), we thought that TNF inhibited the Stat6 pathway. How-
ever, TNF neither suppressed the phosphorylation (Figures 2C
and 2D) nor the nuclear translocation of signal transducer and
activator of transcription 6 (STAT6) (Figure 2E). Furthermore,
TNF did not affect the stability of Arg1 mRNA (data not shown).
To explore whether TNF might act by diminishing the accessi-
bility of transcription factors to the Arg1 promoter and enhancer
regions, we performed chromatin immunoprecipitations (ChIPs)
using an antibody against acetylated lysine 27 of histone H3
(H3K27ac). This histonemark is highly enriched at active cis-reg-
ulatory regions (promoters and enhancers) and directly corre-
lates with chromatin accessibility and transcription of the target
gene (Creyghton et al., 2010; Rada-Iglesias et al., 2011). In line1064 Cell Reports 15, 1062–1075, May 3, 2016with previous results (Ostuni et al., 2013), stimulation of BMMs
with IL-4 triggered a rapid and persistent gain of H3 acetylation
at Arg1 promoter and putative enhancer sites (see Supplemental
Information). Co-administration of TNF to IL-4-stimulated cul-
tures markedly reduced the histone acetylation. TNF-mediated
inhibition of H3 acetylation was maximal at 4 hr and correlated
well with the reduction ofArg1mRNA at the same time point (Fig-
ures 2F and S1G).
Thus, TNF counteracts various components of the IL-4-driven
activation of myeloid cells. This appears to be at least partly due
to an impaired opening of the chromatin, as demonstrated for the
Arg1 promoter and enhancer elements.
Arg1 and Other M2 Marker Are Upregulated in
Tnf/ Mice
To address whether the TNF-mediated suppression of Arg1
also occurred in vivo, we used the C57BL/6 L. major infection
Figure 2. TNF Suppresses IL-4-Induced Oxidative Phosphorylation and Histone Acetylation but Does Not Affect Activation and Trans-
location of STAT6
C57BL/6 BMMs were cultured with or without IL-4 ± TNF for 5 min to 24 hr.
(A) The 24-hr cultures of stimulated BMMs (10 ng/ml IL-4; 50 ng/ml TNF) were analyzed for basal OCR and ECAR. In addition, the OCR response to oligomycin
(ATP synthase inhibitor), carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (uncoupler), or rotenone or anti-mycin (electron transport inhibitors) was
measured. One of four experiments (left). Bar graph panels show means ± SEM of basal OCR, ECAR, and maximal OCR.
(B) A qRT-PCR analysis. Means ± SEM calibrated to medium values of four experiments.
(C and D) STAT6 phosphorylation monitored by STAT6 immunoprecipitation (followed by western blot of pSTAT6 [pTyr641] and reprobing of total STAT6 protein;
C) or by flow cytometry (D). In a parallel western blot, suppression of IL-4-induced Arg1 by TNF was ascertained after 24 hr (not shown). One of five experiments.
(E) Nuclear translocation of STAT6 protein in BMMs after 3 hr of stimulation, visualized by CLSFM after staining with Alexa Fluor 488-conjugated anti-STAT6
(green) and DAPI (nuclei, blue). One of three experiments. Quantification of nuclear STAT6 fluorescence intensity of 100 cells per condition from three experiments
(right panel).
(F) H3K27ac-ChIP of fixed BMMs. Eluted and quantified DNAwas subjected in duplicates to qPCR analysis using primer pairs spanning the Arg1 promoter region
2 or the putative regulatory or enhancer region 4 (see the Supplemental Experimental Procedures). Results of two experiments are shown as relative enrichment
compared to 1% input DNA. Aliquots of the same BMM cultures were analyzed in parallel for Arg1 mRNA by qRT-PCR (right panel).
*p% 0.05; **p% 0.01; ***p < 0.005, ****p < 0.0001, two-tailed Mann-Whitney U test. See also Figure S1G.model. The control of L. major FEBNI strain in C57BL/6 mice
strictly required NOS2 and TNF (Diefenbach et al., 1998; Wil-
helm et al., 2001). Confirming our earlier data (Wilhelm et al.,
2001), C57BL/6 Tnf/ mice infected with L. major showed
more severe skin lesions and higher numbers of parasites at
the site of infection and in the lymphatic organs compared
to C57BL/6 WT controls (Figure S2A). We observed upregula-tion of the mRNA (Figure 3A), protein, and activity of Arg1 (Fig-
ure 3B and S2B–S2E) in the tissues of L. major-infected Tnf/
mice. Skin lesions of WT mice contained substantially higher
amounts of Arg1 than did draining lymph nodes (dLNs).
Consequently, the differences in Arg1 expression between
Tnf/ and WT mice were more prominent in dLNs than at
the site of infection. Unlike with Arg1, infected WT and Tnf/Cell Reports 15, 1062–1075, May 3, 2016 1065
Figure 3. Arg1 and Other M2 Markers Are Upregulated in L. major-Infected Tnf/ Mice
C57BL/6 WT and Tnf/ mice were infected with L. major.
(A and C) qRT-PCR analysis of Arg1 and Nos2 in skin lesions and dLNs (A) or of Ifng and Il4 in dLNs (C) at different days after infection (means ± SEM of four
experiments, with two or three mice per group and time point).
(B) Western blot of skin lesions and dLNs. One of five experiments, with three or four mice per group and time point.
(D) A qRT-PCR analysis of CD11b+ cells sorted from dLNs (21–27 days post-infection [dpi]) (means ± SEM of three experiments, with four mice per group).
(E) CLSFM of dLN sections (18 dpi) stained with anti-Arg1 or anti-CD206 antibodies and DAPI (nuclei, blue). The image is representative of three or four mice per
group and two experiments.
(F) Flow cytometry of cell suspensions of skin lesions (23–29 dpi) from two or threemice per group and time point, whichwere pooled before staining.Within viable
CD45+ cells excluding doublets (Figure S3A) Arg1+ cells were gated (red) and analyzed for the expression of surfacemarkers (red, surfacemarker; gray, isotype or
fluorescence minus one control; number, mean fluorescence value). One of four experiments.
*p < 0.05; **p < 0.01; ***p < 0.005, two-tailed Mann-Whitney U test. See also Figure S2.mice had similar amounts of Nos2 mRNA in the skin lesions
and dLNs (Figure 3A), whereas the expression of NOS2 pro-
tein in total organ lysates of Tnf/ mice was tentatively
(skin) or significantly (dLN) lower than in WT controls (Figures
3B and S2B).
The enhanced expression of Arg1 in L. major-infected Tnf/
mice is unlikely to result from a cytokine imbalance in this mouse
strain, because there was no significant increase of Il4 or lack of
Ifng mRNA in Tnf/ compared to WT mice (Figure 3C). At later
time points, the expression of Ifng was even enhanced in in-
fected Tnf/ mice, demonstrating that Tnf/ mice were fully
capable of mounting a Th1 response to the increased parasite
burden.1066 Cell Reports 15, 1062–1075, May 3, 2016In CD11b+ myeloid cells sorted from the dLNs of Tnf/ mice
at day 21 to day 27 of L. major infection, the expression of Arg1
and of other genes related to alternatively activated macro-
phages (e.g., Ym1 and Mrc1) was significantly upregulated,
whereas the amounts of Nos2mRNA were comparable in Tnf/
versus WT cells (Figure 3D). Confocal laser scanning fluores-
cence microscopy (CLSFM) analysis confirmed the increased
Mrc1 (CD206) expression in Tnf/ dLNs on the protein level
(Figure 3E).
Together, these data show that TNF, apart from its partici-
pation in the induction of NOS2, restricts the in vivo expres-
sion of Arg1 and of other IL-4-dependent genes in myeloid
cells.
Increased Frequency of Arg1+NOS2+ Myeloid Cells in
L. major-Infected Tnf/ Mice
In addition tomyeloid cells, Arg1 and NOS2 can be expressed by
endothelial cells and fibroblasts (Morris, 2009; Witte et al., 2002).
To define the cell population that accounts for Arg1 expression in
C57BL/6 WT and Tnf/ mice during L. major infection, single-
cell analyses using multicolor flow cytometry were performed
(for the gating strategy, see Figure S3A). In the skin lesions of
WT mice, Arg1 was detected in CD11b+CD11c+MHCII+ cells
that were stained for other surface molecules in different combi-
nations, including at least two of the previously mentioned
markers. Co-expression was seen for CD64, Ly6C, CCR2,
Ly6G, F4/80, Relma, CD206, and PDL2 (Figure 3F). Arg1+ cells
were not detected in the CD45 population (Figure S3B). The
specificity of Arg1 staining was verified by isotype controls and
by the absence of Arg1+ cells in Arg1-deficient C57BL/6 mice
(Figures 3F and S3C). Although we cannot formally exclude the
existence of subsets within the Arg1+ cells (because not all
markers were stained in one sample), our data strongly point
to one major Arg1+ cell population. The surface phenotype of
the Arg1+ cells in the skin lesions identifies them as monocyte-
derived inflammatory cells and allows them to be categorized
either as dendritic cells or as macrophages (Fromm et al.,
2012; Gautier et al., 2012; Tamoutounour et al., 2013).
The surface markers of the Arg1+ cells were identical in WT
and Tnf/ mice. However, in line with the mRNA analyses
of sorted CD11b+ cells (Figure 3D), the levels of M2 markers
(Relma, CD206, PDL2) were considerably higher in Arg1+ cells
from Tnf/ mice, as was the expression of Ly6C and CCR2,
whereas CD11c and F4/80 were reduced on Arg1+ cells from
Tnf/ mice compared to WT controls (Figure 3F). Notably, the
overall percentage of Arg1+ cells was 2.14 (±0.32)-fold greater
in Tnf/ lesions than in WT lesions (mean ± SD of three experi-
ments) (Figure 3F), which corroborates our western blot and
CLSFM data. In two Tnf/ mice, we detected the same Arg1+
cells in dLNs, but the weaker expression of Arg1 and the limited
sensitivity of flow cytometry precluded their routine detection in
this organ (data not shown).
Because the size, granularity, and surface phenotype of
NOS2+ cells (Figures S3A and S3D) and of Arg1+ cells (Figures
3F and S3A) were similar, we specifically assessed the potential
co-expression of Arg1 and NOS2. As depicted in Figure 4A,
the CD11b+ cell population of skin lesions from Tnf/mice con-
tained 2.2 (±0.68)-fold fewer NOS2+ cells than did WT lesions
(mean ± SD of three experiments). In addition, almost all
NOS2+ cells from Tnf/ mice, but only around 50% from WT
mice, co-expressed Arg1, and the mean fluorescence signal
for Arg1 was higher in NOS2+ cells from skin lesions of Tnf/
mice. Overall, the percentage of Arg1+NOS2+ cells was 2.42
(±0.7)-fold higher in Tnf/ compared to WT mice (Figure 4A).
Thus, the preponderance of single-positive NOS2+ cells seen
in the myeloid cell population of WT mice is shifted toward NO-
S2+Arg1high double-positive cells in the absence of TNF.
In activated macrophages, NOS2 activity is equally distributed
between the cytosol and a vesicular compartment (Bogdan,
2015). We therefore investigated the extent to which NOS2 and
Arg1 co-localize when induced in one cell. Super-resolution
microscopy of NOS2+Arg1+ BMMs (stimulated with IL-4 plusIFN-g/lipopolysaccharide [LPS]) revealed overlapping expres-
sion of NOS2 and Arg1 in the cytoplasm, whereas the punctate
(vesicular) NOS2+ structures remained Arg1 negative (Figure 4B).
Hyperexpression of Arg1 in Tnf/ Mice Impairs the
Production of NO
Arginine depletion by Arg1 can inhibit NO production (due to
substrate competition) or even downregulate NOS2 protein
(El-Gayar et al., 2003; Rutschman et al., 2001). Because Arg1
and NOS2 were co-expressed within the same cell, we tested
whether Arg1 hyperexpression in Tnf/ mice correlates with
reduced activity of NOS2 in situ.
CLSFM analysis of skin lesions confirmed not only the pres-
ence of NOS2+, Arg1+, or NOS2+Arg1+ myeloid cells but also
the substantially higher amounts of Arg1 (both in terms of cell
number and MFI) and lower expression of NOS2 (cell number)
in Tnf/ mice compared to WT controls (Figures 4C, a versus
b, and 4E; Figure S4A, a versus b). Leishmania parasites were
preferentially found in Arg1+ foci and were more abundant in
Tnf/ lesions (Figure 4C, a versus b). The dLNs of Tnf/ mice
also contained more Arg1+ cells and parasites than the respec-
tive WT organs, whereas the number of NOS2+ cells was slightly
reduced in Tnf/ dLNs (Figures 4D, a versus b, and 4E; Fig-
ure S4A, c versus d).
NO is a precursor of peroxynitrite that causes tyrosine nitration
of proteins and thereby acts as a footprint of NOS2 activity in tis-
sues (Bogdan, 2015). Anti-nitrotyrosine staining of skin and dLN
sections from L. major-infected WT mice yielded significantly
stronger signals (number andMFI of positive cells) than in tissues
from Tnf/mice (Figures 4C and 4D, c versus d, and 4F). Nitro-
tyrosine+ cells stained positively for CD11b (Figures 4C and 4D,
c versus d). In serial sections of Tnf/ dLNs, expression of Arg1
by CD11b+ cells correlated with a lack of nitrotyrosine staining
despite the presence of NOS2 protein (Figure S4B). The nitrotyr-
osine staining was absent in tissue sections from naive C57BL/6
and infected Nos2/ mice (Figures S4C, a versus b, and S4D)
and after blocking of the anti-serum with 3-nitro-L-tyrosine
(data not shown). To verify that the reduced nitrotyrosine staining
in Tnf/mice reflects a lack of locally produced NO, we treated
the sections with the NO-reactive compound 1,2-diamino-
anthraquinone (DAQ). More NO was detected in infected dLNs
of WT mice compared to dLNs of Tnf/ mice (Figures 4G and
S4E). Serial sections from infected Nos2/ mice gave no signal
with DAQ, despite the presence of CD11b+ cells (Figure S4C,
c versus d).
Together, these results show that Arg1 hyperexpression in
Tnf/mice impairs the local production of NO and subsequently
the control of Leishmania parasites.
Arg1 Expression Accounts for the Non-healing Course
of L. major Infection
To test whether the increased Arg1 expression in Tnf/ mice
contributed to the detrimental course of L. major infection,
we treated L. major-infected C57BL/6 WT or Tnf/ mice with
Nu-hydroxy-nor-L-arginine (nor-NOHA). Nor-NOHA, an arginine
inhibitor that is neither tissue nor isoform selective (because it
also blocks the arginine 2 isoform) (Custot et al., 1997), did not
impede the arginase of L. major (Kropf et al., 2005) (data notCell Reports 15, 1062–1075, May 3, 2016 1067
Figure 4. Increased Frequency of Arg1+NOS2+ Myeloid Cells Correlates with Decreased Detection of Nitrotyrosine and NO in Tnf/ Mice
(A and C–G) C57BL/6 WT and Tnf/ mice were infected with L. major. (A) Flow cytometry of skin lesions (23–29 dpi). NOS2+ cells within viable CD11b+CD45+
single cells were gated and analyzed for co-expression of Arg1. The percentage of Arg1+NOS2+ cells within the NOS2+ population was determined. One of three
experiments.
(B) BMMs were stimulated with IL-4 (10 ng/ml) or IFN-g (20 ng/ml) plus LPS (200 ng/ml) for 24 hr. Co-localization of Arg1 and NOS2 was analyzed by super-
resolution microscopy. One of five experiments.
(C and D) Serial sections from skin lesions (C) or dLNs (D) at 26 dpi were stained for Arg1 (green), NOS2 (red), and L. major (magenta) (a and b) or for nitrotyrosine
(green) and CD11b (white) (c and d). Nuclei staining with DAPI (blue). Due to marked differences in signal strength, exposure times had to be reduced for Arg1
(green) in skin sections of Tnf/ mice. Representative images from one of four experiments, with three or four mice per group and time point (19–29 dpi).
(E and F) Quantification of the number andmean fluorescence intensity (MFI) of Arg1- or NOS2-positive cells (E) or nitrotyrosine-positive cells (F) in tissue sections
of WT versus Tnf/ mice (19–29 dpi). The target MFI was normalized to the fluorescence signal of DAPI. The number of positive cells was determined per 100
nuclei. Three or four visual fields (3200) per tissue section were evaluated. Analysis was of 17 dLNs and lesions of WT and Tnf/ mice from four experiments.
(G) CLSFM of serial sections of dLNs from WT versus Tnf/ mice stained for NO using DAQ (green) (a and c) or for NOS2 (red) and CD11b (white) (b and d).
Representative images of four experiments, with three or four mice per group and time point (18–34 dpi).
**p < 0.01; ***p < 0.0001, two-tailed Mann-Whitney U test. See also Figures S3 and S4.shown) but was reported to ameliorate the severity of L. major
skin lesions in BALB/c mice (Iniesta et al., 2005; Kropf et al.,
2005). Although in our hands this compound potently blocked
Arg1 in macrophages in vitro (El-Gayar et al., 2003), the clinical
course of L. major infection and the parasite loads in nor-
NOHA-treated C57BL/6 WT or Tnf/ mice were indistinguish-
able from the respective controls (data not shown). Furthermore,
when testing nor-NOHA in L. major-infected BALB/c mice,1068 Cell Reports 15, 1062–1075, May 3, 2016neither local nor systemic application led to consistent pro-
tective effects (data not shown). We therefore abandoned the
pharmacological approach and resorted to a model of cell-
type-specific deletion of the Arg1 gene using Tie2cre+/Arg1fl/fl
mice (El Kasmi et al., 2008). The Tie2cre deleter is active in
hematopoietic and endothelial cells. However, because Arg1
expression in L. major-infected mice was confined to CD45+
cells (Figure S3B) identified as myeloid cells (Figure 3F),
Figure 5. L. major-Infected BALB/c Mice Express Increased Levels of Arg1 in the Skin Lesions and dLNs Compared to Self-healing
C57BL/6 Mice
BALB/c versus C57BL/6 or BALB/cWT versus Il4/Il13/mice were infectedwith L. major. Skin lesions and dLN tissuewere analyzed at the time points indicated.
(A) A qRT-PCR analysis (means ± SEM from two experiments, with six mice per group and time point).
(B) Western blot analysis. One of four experiments.
(C) Arginase activity in protein lysates of skin lesions and dLNs (means ± SEM from two or three experiments, with three mice per group and time point).
(D) Western blot analysis. One of two experiments.
*p < 0.05; **p < 0.01; ***p < 0.005, two-tailed Mann-Whitney U test. See also Figures S5 and S6.Tie2cre+/Arg1fl/fl mice are an efficient means of achieving
myeloid-specific deletion of Arg1 (Duque-Correa et al., 2014).
Tie2cre+/Arg1fl/fl mice were backcrossed to BALB/c. We
chose the BALB/c background because similar to C57BL/6
Tnf/ mice (Figure S2A), BALB/c WT mice developed progres-
sive disease after L. major infection (Figure S5A). The amounts of
Arg1 mRNA, protein, and activity in the skin lesions (Iniesta et al.,
2005; Kropf et al., 2005) and dLNs of L. major-infected BALB/c
mice were higher than in self-healing C57BL/6 mice (Figures
5A–5C, S5B, and S5C). In both strains of mice, Arg1 was more
prominent in the skin than in dLNs, which is in line with the differ-
ential expression of IL-4 at these two sites (Figure 5A). Despite
comparable quantities of Nos2 mRNA in BALB/c and C57BL/6
mice (Figure 5A), NOS2 protein was markedly reduced in
L. major-infected BALB/c mice (Figure 5B). The reciprocal
expression of Arg1 and NOS2 protein suggests that the trans-
lational control of NOS2 by Arg1 activity observed in vitro (El-
Gayar et al., 2003) also occurs in vivo.
In BALB/c mice, the increased amounts of Arg1 were accom-
panied by persistent Il4mRNA and reduced levels of Ifng and Tnf
mRNA (Figure 5A). To test whether the Th2 cytokine milieu and
Arg1 hyperexpression were causally linked, we used Il4/ orIL-4/IL-13-double-deficient BALB/c mice. Unlike BALB/c WT
mice, both Il4/ and Il4/Il13/ mice contained the infection
(Figures S5D and S5G) and showed a strong reduction (lesions)
or abolition (dLNs) of Arg1 mRNA and protein expression (Fig-
ures 5D, S5E, S5F, and S5H–S5J). The residual amount of
Arg1 in the skin lesions of Il4/Il13/ mice might reflect the
activity of other Arg1-inducing cytokines or of microbial ligands.
The Arg1+ myeloid cell population in skin lesions of L. major-in-
fected BALB/c WT mice showed the same surface phenotype
(i.e.,CD11b+CD11c+MHCII+Ly6C+CD64+PDL2+CD207CCR7)
(Figure S6), as seen in C57BL/6 WT and Tnf/ mice.
As expected, Arg1-expressing Tie2cre/Arg1fl/fl or Tie2cre+/
Arg1wt/wt BALB/c mice developed ulcerative skin lesions and
visceral disease following L. major infection. In contrast, the
Arg1-deficient Tie2cre+/Arg1fl/fl littermates presented only
small, non-ulcerative and non-progressive skin swellings after
low (1 3 104) infection inocula (data not shown) or high (3 3
106) infection inocula (Figure 6A) and showed a significantly
reduced parasite burden at the site of infection, in the
dLNs, and in the spleen (Figure 6B). No spontaneous reacti-
vation of disease in Tie2cre+/Arg1fl/fl BALB/c mice occurred
during the observation period (%274 days) (Figure 6C). TheCell Reports 15, 1062–1075, May 3, 2016 1069
Figure 6. Arg1-Deficient BALB/c Mice Are
Protected from Progressive Cutaneous
Leishmaniasis
Arg1-deficient BALB/c mice (Tie2cre+/Arg1fl/fl)
and control littermates (Tie2cre+/Arg1wt/wt or
Tie2cre/Arg1fl/fl) were infected with L. major.
(A and C) Clinical course of infection. Six to nine (A)
or four to six (C)micewere usedper group (means±
SEM). One of six (A) or two (C) experiments. y, mice
had to be euthanized for ethical reasons.
(B) Parasite numbers in the tissues (results
represent the mean of 9–12 mice that were
analyzed in three or four experiments, with 3 mice
per group and time point).
(D)Flowcytometryofskin lesions (23dpi).Cellswere
gated on viable single CD45+ cells (Figure S3A), and
the percentage of Arg1+, NOS2+, or Arg1+NOS2+
cells was determined using the respective isotype
controls. One of two experiments.
*p < 0.05; **p < 0.01; ***p < 0.005, two-tailed
Mann-Whitney U test. See also Figures S7A
and S7B.efficiency of deletion of Arg1 expression was >99.5% (Fig-
ures 6D, S7A, and S7B).
Analyses of infected tissues revealed a slight but signif-
icant reduction of Il10 mRNA in the dLNs from Arg1-deficient
Tie2cre+/Arg1fl/fl BALB/c mice, whereas Ifng and Il4 mRNAs
remained unaltered (Figure 7A). Considering that Arg1 activity
can diminish the availability of L-arginine and thereby might
affect T cell differentiation and/or proliferation (Bogdan, 2015;
Duque-Correa et al., 2014; Munder et al., 2009; Pesce et al.,
2009), we studied the T cell response in L. major-infected
Tie2cre/Arg1fl/fl BALB/c versus Tie2cre+/Arg1fl/fl BALB/c
mice. First, CD4+CD3+ T cells of dLNs from both mouse strains
were analyzed for their expression of the transcription factors
T-bet (Th1), GATA3 (Th2), and RORgt (Th17) to evaluate the
expansion of T helper cell subsets. Whereas T-bet+ or RORgt+
CD4+ T cells were hardly detectable, the high percentage of
GATA3+ T cells in both WT and Arg1-deficient dLNs demon-
strated a sustained Th2 response (Figure 7B). Despite a signifi-
cantly reduced (30%) frequency of CD4+GATA3+ T cells at later
time points of infection in the Arg1-deficient BALB/c mice, the Il4
mRNA expression was altered in neither whole dLNs (Figure 7A)
nor sorted CD4+CD3+ dLN cells (Figure 7C). Thus, the net
response of Th2 effector cells was not reduced in Arg1-deficient
BALB/c mice. Second, the expression of Ifng, Il10, and Il17a or
Il17f mRNA was comparable in CD4+ or CD8+ T cells sorted
from both groups of mice (Figure 7C). Third, there was no dif-
ference in the percentage of Foxp3+CD4+ regulatory T (Treg)
cells in the dLNs at different time points of infection (Figure 7D).
Finally, when we measured the proliferative capacity of CD4+ or
CD8+ T cells in vivo using bromodeoxyuridine (BrdU) incorpo-
ration, absence of Arg1 was associated with either unaltered1070 Cell Reports 15, 1062–1075, May 3, 2016(two experiments) or slightly reduced
(one experiment) but not with improved
T cell proliferation (Figure 7E).
The deletion of Arg1 did not lead to up-
regulation ofNos2mRNA or protein at thesite of infection or in the dLNs; the qRT-PCR analyses and the
western blot experiments even revealed slightly diminished
Nos2 mRNA and protein expression in Arg1-deficient mice (Fig-
ures 7A, 7F, and S7A). Nevertheless, Arg1 deficiency caused a
marked increase of nitrotyrosine-positive cells and of the pro-
duction of NO (as detected by DAQ) in the skin lesions and
dLNs (Figure 7G, S7C, and S7D).
Taken together, these data allow us to conclude that hyper-
expression of Arg1, as seen in non-healing BALB/c or C57BL/6
Tnf/ mice, does not deviate the T cell response against
L. major but markedly impairs the in situ generation of protective
NO and thereby interferes with disease control.
DISCUSSION
TNF as Regulator of Immune Responses
TNF is best known for its potent proinflammatory effects result-
ing from its ability to promote the proliferation or enhance the
function of macrophages, dendritic cells, B lymphocytes, T lym-
phocytes, natural killer cells, and other types of immune cells
(Vassalli, 1992). While this immunostimulatory function of TNF
confers protection of the host organism against infectious path-
ogens (Flynn et al., 1995; Grivennikov et al., 2005; Ko¨rner et al.,
2010; Marino et al., 1997; Novosad and Winthrop, 2014; Pfeffer
et al., 1993; Vassalli, 1992), overproduction of TNF is a typical
feature of autoimmune and other chronic inflammatory diseases,
leading to tissue destruction in mice and humans (Atreya et al.,
2014; Riminton et al., 1998; Vassalli, 1992). Previous studies
showed that TNF can mediate control of intracellular infections
by the stimulation of the anti-microbial activity of phagocytes
(Bogdan, 2015; Yazdanpanah et al., 2009); the activation of
Figure 7. Increased NO Production but Unaltered T Cell Response in Arg1-Deficient BALB/c Mice
Arg1-deficient BALB/c mice (Tie2cre+/Arg1fl/fl) and control littermates (Tie2cre+/Arg1wt/wt or Tie2cre/Arg1fl/fl) were infected with L. major.
(A) A qRT-PCR analysis (means ± SEM of three experiments, with three or four mice per group and time point).
(B) The dLN cells (stained for CD3, CD4, CD8, and NKp46 and T-bet, GATA3, or RORgt) were gated on viable CD3+CD4+CD8Nkp46 cells, and the percentage
of T-bet-, GATA3-, or RORgt-positive cells was determined. Representative dot plots and means of three experiments, with two to four mice per group and time
point.
(C) A qRT-PCR analysis of CD3+CD4+ and CD3+CD8+ T cells sorted from the dLNs of infected mice (three per group) at 17–22 dpi. Means ± SEM of three
experiments.
(D) The dLN cells (stained for CD3, CD4, CD8, and Foxp3) were gated on viable CD3+CD4+CD8 T cells, and the percentage of Foxp3+ Treg cells was determined.
Representative dot plots and means of four experiments, with two to four mice per group and time point.
(E) The dLN cells from BrdU-injected mice were stained for CD3, CD4, CD8, and BrdU. BrdU+ cells (excluding doublets and dead cells) within the CD3+CD4+ or
CD3+CD8+ T cell population were gated. Representative dot plots and means of three experiments, with three mice per group and time point. The dLN cells from
infected WT mice without BrdU treatment were used as controls for the BrdU staining.
(F) Western blot analysis of skin lesions and dLNs (18 dpi). One of five experiments, with three or four mice per group and time point.
(G) CLSFM analysis of dLNs that were stained for nitrotyrosine (green) and NOS2 (red) (a and b) and in serial sections for NO (c and d) visualized by DAQ (green)
and for NOS2 (red) and CD11b (white) (e and f). Nuclei were stained with DAPI (blue). Representative images from three experiments, with four mice per group and
time point analyzed at 17–32 dpi.
*p < 0.05, two-tailed Mann-Whitney U test. See also Figures S7C and S7D.T helper cells or cytotoxic T cells (Vassalli, 1992); the differentia-
tion, functional maturation, or survival of myeloid cells (Caux
et al., 1992; Fromm et al., 2012; Sade-Feldman et al., 2013);
and the generation of non-necrotizing granulomas (Flynn et al.,
1995; Marino et al., 1997).
Our present work revealed that TNF downregulated Arg1
in vitro and in vivo and thereby unleashed the enzymatic activityof NOS2 and the production of NO. TNF also antagonized
other aspects of macrophage activation by IL-4, including the
IL-4-induced oxidative metabolism. TNF did not inhibit the phos-
phorylation or nuclear translocation of STAT6 but suppressed
IL-4-triggered histone acetylation of the Arg1 promoter and pu-
tative regulatory or enhancer regions, which is likely to impede
access or binding of STAT6 to these sites and/or its assemblyCell Reports 15, 1062–1075, May 3, 2016 1071
with other relevant transcription factors (e.g., C/EBPb) (Pauleau
et al., 2004; Sheldon et al., 2013). We currently investigate
whether TNF regulates histone acetyl-transferases or deacety-
lases, which are critical for the induction of Arg1 by IL-4 (Serrat
et al., 2012). Hyperexpression of Arg1, resulting from the failure
to shut down IL-4 or the lack of TNF, presumably accounts for
the exquisite L. major susceptibility of BALB/c or Tnf/ mice,
respectively, because deletion of Arg1 alone was sufficient to
restore local NO production and to prevent non-healing disease
in BALB/c mice. Furthermore, we defined inflammatory mono-
cyte-derived dendritic cells or macrophages as the principle
source of Arg1 at the infection site. The high rate of intracellular
co-expression of Arg1 and NOS2 seen by high-resolution micro-
scopy in IL-4/IFN-g/LPS-stimulated macrophages in vitro and in
infected Tnf/ mice facilitated the ability of Arg1 to effectively
impair the production of NO in situ.
Earlier studies reported upregulation of Arg1 by TNF in endo-
thelial cells in a model of coronary ischemia and reperfusion
injury (Gao et al., 2007) or in myeloid suppressor cells during
chronic inflammation elicited by repeated subcutaneous injec-
tions of heat-killedMycobacterium bovisBacille Calmette Guerin
(Sade-Feldman et al., 2013). While these experimental settings
were entirely different from the infectionmodel used here, our re-
sults do not exclude a divergent role of TNF during infections
with other pathogens or in other organs.
Arginase and Pathogen Control
Arg1 expression might impair anti-microbial defense in vivo by
three mechanisms (Bogdan, 2015): (1) Arg1 can deplete myeloid
cells of L-arginine, thereby impeding the generation of NO by
NOS2; (2) Arg1 of myeloid cells is capable of depriving T lympho-
cytes of L-arginine, which was reported to decrease their prolif-
eration, survival, and/or expression of costimulatory molecules
in vitro; and (3) Arg1 activity leads to the generation of ornithine
and via the ornithine decarboxylase (ODC) pathway to the syn-
thesis of polyamines, which are essential for the growth of
various parasites, including Leishmania (Colotti and Ilari, 2011).
However, as L. major expresses its own arginase and ODC
(Reguera et al., 2009), its survival is unlikely to be affected by
exogenous polyamines derived from host cells. With respect
to the second possible mechanism of Arg1 action, we avoided
the use of in vitro culture systems, which are prone to distort
the true proliferative capacity of T cells due to the high L-arginine
content of the culture media. Instead, we studied the differen-
tiation and proliferation of CD4+ or CD8+ T cells in vivo using
Tie2cre/Arg1fl/fl or Tie2cre+/Arg1fl/fl mice. These analyses re-
vealed an unaltered proliferation of T cells in situ without any
apparent shift in the T helper cell differentiation, the abundance
of Treg cells, or the expression of T helper cell cytokines, irre-
spective of the presence or absence of Arg1. In contrast, the
generation of NO by NOS2 was severely impaired when Arg1
was hyperexpressed. Thus, our data clearly show that the coun-
terprotective function of Arg1 primarily results from its competi-
tion with NOS2.
TNF and Leishmaniasis
Previous studies emphasized the role of TNF as a co-activator of
macrophages for the expression of NOS2 activity. Exogenous or1072 Cell Reports 15, 1062–1075, May 3, 2016endogenous TNF clearly synergized with IFN-g for the induction
of NOS2/NO in inflammatory macrophages in vitro (Wilhelm
et al., 2001) and in vivo (Olekhnovitchet al., 2014) and for the killing
of intracellularLeishmaniaparasites (Green et al., 1990; Liewet al.,
1990). At least in BMMs, TNFmight induceNOS2 even on its own,
as shown in the present study (Figures 1A and 1F). So far, it has
been assumed that the remarkable susceptibility to L. major
seen in mice lacking TNF (Allenbach et al., 2008; Titus et al.,
1989;Wilhelmet al., 2001) results from impairedmacrophageacti-
vation. However, TNFR1/TNFR2 double-deficient mice (Nashlea-
nas et al., 1998) and Tnf/ mice (Wilhelm et al., 2001; De Trez
et al., 2009)maintained the expression ofNos2mRNAand protein
in the dLNs, and L. major-infectedmacrophages from these mice
were still capable of expressing NOS2 and killing intracellular par-
asites in response to IFN-g (Nashleanas et al., 1998). These find-
ings already indicated that the synergism with IFN-g might not
be the only or leading mechanism of action of TNF in vivo.
Our study demonstrates that TNF suppresses the IL-4-depen-
dent expression of Arg1 in myeloid cells and thereby generates a
micromilieu that allows for enhanced generation of NO by NOS2
in situ and improved parasite control. It will be of interest to
assess whether TNF functions in the same way in patients with
autoimmune diseases, who have an increased risk to develop
severe infections with Leishmania or other intracellular patho-
gens following anti-TNF treatment (Novosad and Winthrop,
2014; Tung Chen et al., 2014). The observations that TNF
signaling antagonized M2 gene expression in spinal cord injury
(Kroner et al., 2014) and in solid tumors (Kratochvill et al.,
2015) and that two other TNF superfamily members (BAFF and
APRIL) caused downregulation of M2 markers (Allman et al.,
2015) suggest that the suppression of Arg1 by TNF and TNF-
related molecules forms a general paradigm in immunology.
Considering that Arg1-expressing myeloid cells contribute to
the pathogenesis of numerous diseases, ranging from chronic
infections to malignant tumors and progressive organ fibrosis,
our findings have implications for novel treatment strategies
and call for caution when using TNF-neutralizing agents.
EXPERIMENTAL PROCEDURES
Mouse Strains
C57BL/6 or BALB/c WT or transgenic mice (C57BL/6 Tnf/, C57BL/6
Nos2/, BALB/c Il4/, BALB/c Il4/Il13/, conditional Arg1-deficient
BALB/c or C57BL/6 mice [Tie2Cre+/Arg1fl/fl versus Tie2Cre+/Arg1wt/wt or
Tie2Cre/Arg1fl/fl]) were used at 8–14 weeks of age. Infections were per-
formed with female mice and the respective age-matched WT or littermate
controls. Mice were kept under SPF conditions. Animal care and experiments
were conducted in accordance with German regulations after local govern-
mental approval (Freiburg, Ansbach and W€urzburg, Germany).
Infection and In Vivo Treatment of Mice
Mice were infected bilaterally into the skin of the hindfoot with 3 3 106 sta-
tionary-phase L. major promastigotes (strain MHOM/IL/81/FEBNI) in 50 ml
PBS. The clinical monitoring of the infection by measuring the footpad thick-
ness, the determination of the parasite burden by limiting dilution analyses,
and the applications of drugs are described in the Supplemental Experimental
Procedures.
Cell Culture and Measurements of Cellular Activities
BMDCs and BMMs were generated from bone marrow cells (Prajeeth
et al., 2011) and used at day 7 or 8 to day 10 of culture, respectively. Then,
recombinant mouse interleukin-4 (0.5–10 ng/ml) and recombinant mouse
tumor necrosis factor (10 or 50 ng/ml) (R&D Systems) were added as the stim-
ulant or stimulants. At the concentrations used, the LPS content of all reagents
and the supplemented media was %10 pg/ml (colorimetric Limulus amebo-
cyte lysate assay, Whittaker M.A. Bioproducts).
The composition of the culture media and the determination of nitrite, argi-
nase activity, and energy metabolism (OCR and ECAR) are described in the
Supplemental Experimental Procedures.
qPCR
Total RNA was extracted from homogenized tissue or cultured cells using the
TRIfast reagent (Peqlab). Then, 1–5 mg RNA were reverse transcribed using the
High-Capacity cDNAArchiveKit (ThermoFisherScientific).Next, qPCRwasper-
formed on the ABI7900HT Fast Real Time PCR system (Applied Biosystems;
Thermo Fisher Scientific). For the gene-specific assays used, see the Supple-
mental Experimental Procedures. The mRNA levels were calculated using the
following formula: relative expression = 2(CT(Target)
C
T(Endogenous control)
) 3 f,
with f = 104 as an arbitrary factor. In some experiments, relative expression
was calibrated to controls, as indicated in the legends.
ChIP
ChIP was performed as described (Garber et al., 2012; Ostuni et al., 2013). In
brief, nuclear extracts obtained from 12 3 106 fixed BMMs were sheared by
sonication and incubated overnight at 4C with protein G Dynabeads (Invitro-
gen), coupled with 2.5 mg of anti-H3K27ac antibody (ab4729, Abcam). After
ChIP, beads were magnetically recovered and washed and DNA was eluted
and decrosslinked overnight at 65C. DNA was then purified with solid-phase
reversible immobilization beads (Agencourt AMPure XP, Beckman Coulter)
and quantified with PicoGreen (Invitrogen). For ChIP-qPCR experiments, 1 ml
of purified DNA (immunoprecipitation and 1% input) was used for amplification
on an ABI7500 machine. Primers are listed in the Supplemental Experimental
Procedures.
Flow Cytometry
See the Supplemental Experimental Procedures.
Western Blot Analysis and Immunoprecipitations
See the Supplemental Experimental Procedures.
Immunohistology and Microscopy
See the Supplemental Experimental Procedures.
Statistical Analyses
Results are displayed as mean ± SEM and were statistically analyzed using
GraphPad Prism v.4 or v.6, as detailed in the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2016.04.001.
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